Market Overview:
The global hydroxychloroquine market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to exhibit robust growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hydroxychloroquine (HCQ), with the chemical formula C18H26ClN3O, is a chemotherapeutic agent drug that is primarily used for the prevention and treatment of malaria. It acts against erythrocytic forms of malarial parasites and is majorly administered in the form of an oral tablet. It is also used for the treatment of various other diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Q fever and Porphyria Cutanea Tarda (PCT) and is being examined for the possible treatment of the rapidly spreading COVID-19 disease. It exhibits immunosuppressive, anti-autophagy and antimalarial properties as it suppresses immune functions and presents antigens and cytokines in the body.

The sudden outbreak of the COVID-19 pandemic across the globe is one of the key factors driving the growth of the market. Various clinical trials and experiments are being conducted across the globe to analyze the efficacy and safety of hydroxychloroquine for the treatment of adults hospitalized with the coronavirus disease. The increasing prevalence of malaria and various other chronic diseases, especially in developing and underdeveloped countries, is also leading to the widespread adoption of this drug. In line with this, the rapidly rising cases of autoimmune diseases, such as lupus erythematosus and rheumatoid arthritis, are acting as another growth-inducing factor. Other factors, including the implementation of favorable government policies to promote global health, along with extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hydroxychloroquine market report, along with forecasts for growth at the global and regional level from 2021-2026. Our report has categorized the market based on dosage type, distribution, application, grade and route of administration.
Breakup by Dosage Type:
- 200 Mg
- 300 Mg
- 400 Mg
- Others
Breakup by Distribution:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Application:
- Rheumatoid Arthritis
- Lupus Erythematosus
- Malaria
- Coronavirus (COVID-19)
- Others
Breakup by Grade:
- USP Standards Grade
- EP Standards Grade
- Pharmaceutical Standards Grade
- Others
Breakup by Route of Administration:
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Amneal Pharmaceuticals Inc., Cardinal Health Inc., Cipla Ltd., Ipca Laboratories Ltd., Laurus Labs, Lupin Limited, Mylan N.V., Novartis AG, Prasco Laboratories, Dr. Reddy’s Laboratories Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Torrent Pharma, Zydus Cadila, etc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2020 |
Historical Period |
2015-2020 |
Forecast Period |
2021-2026 |
Units |
US$ Billion |
Segment Coverage |
Dosage Type, Distribution, Application, Grade, Route of Administration, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Amneal Pharmaceuticals Inc., Cardinal Health Inc., Cipla Ltd., Ipca Laboratories Ltd., Laurus Labs, Lupin Limited, Mylan N.V., Novartis AG, Prasco Laboratories, Dr. Reddy’s Laboratories Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Torrent Pharma and Zydus Cadila |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global hydroxychloroquine market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global hydroxychloroquine market?
- What is the breakup of the market based on the dosage type?
- What is the breakup of the market based on the distribution?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the grade?
- What is the breakup of the market based on the route of administration?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global hydroxychloroquine market and who are the key players?
- What is the degree of competition in the industry?